Company & Sponsor Intelligence
Shionogi
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed2
Countries1
Therapeutic footprint
alsstroke
Indexed studies
NCT05151471Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS
als · United StatesPHASE3
als · United StatesPHASE3
NCT05953480A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
stroke · United StatesPHASE2
stroke · United StatesPHASE2
NCT04165824Safety Study of Oral Edaravone Administered in Subjects With ALS
als · United StatesPHASE3
als · United StatesPHASE3
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →